Abstract Renewed interest has arisen in the use of thromboelastography/thromboelastometry in evaluating coagulation kinetics. The test medium, type of activator, and its concentration may influence the interpretation of coagulation kinetics. This study aimed to investigate methodologic influences of activator and test medium on thromboelastometric parameters of coagulation kinetics. Dynamic clot formation was evaluated by thromboelastometry using whole blood (WB), platelet-rich plasma, or platelet-poor plasma employing different concentrations of extrinsic (tissue factor) and contact activator (synthasil) and with variable concentrations of phospholipids. Plasma samples displayed prolonged clot initiation and enhanced clot propagation compared with WB. Clot firmness was markedly reduced in platelet-poor plasma as compared with platelet-rich plasma and WB. Increasing concentration of activator shortened the clot initiation and increased the velocity of clot propagation, whereas terminal clot firmness remained unaffected. Platelets accelerated clot propagation and raised clot firmness. Phospholipids shortened the time of clot initiation and increased velocity of propagation, while clot firmness remained unchanged. Our results demonstrate that evaluation of coagulation kinetics using thromboelastometry varies according to the composition of the test medium, type, and concentration of activator, as well as the presence and concentration of phospholipids in the test reagent.
Introduction
During the past decade, renewed interest has arisen in the use of thromboelastography or thromboelastometry for evaluation of coagulation kinetics [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . These viscoelastic analyses benefit by providing a continuous visualization of physical changes occurring during blood coagulation. Thus, kinetic properties of the entire process of clot formation can be derived by combining traditional parameters, such as clotting time (CT) and maximum clot firmness (MCF) with new dynamic parameters such as maximum velocity of clot formation and the time to maximum velocity of clot formation [8, 13] . Interpretation of the rate-specific characteristics of clot formation requires a critical evaluation of experimental conditions and profound insight of the biological functions of coagulation proteins and blood cells on the overall regulation of coagulation. Additionally, it may be important to consider the importance of phospholipids supporting the enzymatic properties of coagulation factors [14] . Thus, assembly of coagulation factors by calcium-mediated complex bindings between gamma-carboxylated coagulation factors and phospholipids seems crucial for the overall coagulation kinetics. Most commercially available reagents for thromboelastography/thromboelastometry contain activators such as celite, kaolin, or tissue factor preparations in protocols developed for study of whole blood (WB) coagulation. In WB, it seems rational to anticipate that platelets and natural phospholipids are present in physiologically relevant concentrations. However, some studies used platelet-poor plasma (PPP) as test medium in a setup utilizing reagents designed to activate WB coagulation. Moreover, the type of activator (tissue factor versus factor XII activator) may constitute an important determinant in interpretation of coagulation kinetics using thromboelastography/thromboelastometry. As of today, the tissue factor pathway is largely acknowledged as the physiological trigger for in vivo generation of a sufficient hemostatic plug [15, 16] . Nevertheless, several interesting studies adopted traditional contact activation [17] [18] [19] [20] . The final concentration of the activating reagent, whether tissue factor or contact activator, may also influence the characteristics of coagulation kinetics in various coagulopathies. This is exemplified by the completely normal coagulation pattern of factor VIIIdeficient blood if activated by a high concentration of tissue factor reagent, while low concentrations of tissue factor result in a distinctly pathologic and compromised coagulation profile characteristic of severe hemophilia A [8, 21] .
The objectives of the present study were to demonstrate similarities and differences in use of PPP, platelet-rich plasma (PRP), and WB as test medium in thromboelastometric evaluation of coagulation kinetics. Second, experiments were carried out to describe the influence of platelets and phospholipids on coagulation kinetics as well as the impact of different types and concentrations of activators. We challenged the hypotheses that (1) in blood from healthy individuals, thromboelastometric parameters of dynamic coagulation kinetics differ according to the use of PPP, PRP, or WB; (2) addition of natural platelet-derived phospholipids to PPP would induce significant changes in the thromboelastometric parameters of coagulation kinetics; and (3) the type and concentration of activator significantly influences the thromboelastometric parameters of dynamic coagulation.
Materials and methods

Study subjects
Following informed consent, blood samples were drawn from three healthy adult volunteers. All study subjects enrolled were within the normal range of platelet count, prothrombin time, activated partial thromboplastin time, thrombin time, D-dimers, as well as levels of fibrinogen and antithrombin. None of the subjects had used acetylsalicylic acid or nonsteroid anti-inflammatory drugs during 7 days prior to blood sampling.
Thromboelastometry WB coagulation analysis
Continuous dynamic clot formation profiles were recorded using a ROTEM Thromboelastometry Coagulation Analyzer (ROTEM Thromboelastometry; Tem International GmbH, Munich, Germany) consistent with our method described elsewhere [8] . In brief, the citrated WB rested for 30 min at ambient temperature. The thromboelastometry analysis was performed by incubating 300 μl of blood mixture with 20 µl of activator (human recombinant tissue factor or a contact activator). Coagulation was initiated by addition of 20 µl of 200 mM CaCl 2 and all analyses were processed in duplicate and recordings were allowed to proceed for at least 90 min. The digital signal from the ROTEM Analyzer was imported into a software program (DyCoDerivAn GOLD; AvordusoL, Risskov, Denmark) that calculates dynamic velocity profiles of coagulation as well as derived parameters: maximum velocity (MaxVel) [mm*100/s] of clot formation and the time to MaxVel (t, MaxVel; in seconds) [8] . In the present study, the WB clotting process was characterized as clot initiation defined as clotting time (CT), clot propagation phase as defined by MaxVel, and clot firmness defined as maximum clot firmness, or MCF.
Activators
The following are the activators: extrinsic activator, recombinant human tissue factor, (Innovin; Dade Behring, Marburg, Germany), and factor XII/contact activation (Synthasil, 0020006800; Instrumental Laboratory Company, Lexington, MA).
Test media
Whole blood
Using minimum stasis and a 21-gauge butterfly needle, blood samples for coagulation analyses were drawn into citrated plastic tubes (VenoJect tubes; Terumo Europe, Leuven, Belgium; trisodium citrate 0.129 mol/L: 3.2 w/ vol%), at a volume ratio of 1:10. In addition, 3 ml of EDTA blood was collected for blood cell count. Citrated WB rested for 30 min at ambient temperature prior to analysis.
Preparation of freeze-stabilized phospholipid concentrate
A concentrate of natural phospholipids was prepared from an outdated well-blended platelet pool. A mixed portion of 100 ml was transferred to a tube and mixed with 100 ml refrigerated Tris-buffered saline (TBS) buffer (50/150 mM; Bie & Berntsen, Herlev, Denmark). The platelet-buffer mixture was distributed in small aliquots to 20 plastic tubes, and each tube was centrifuged (177 × g, 15 min at 4°C). The supernatants were transferred to new plastic tubes, and approximately 0.5 ml of the sediment containing fragments of red blood cells was discharged. Hence, the supernatants were centrifuged (2,800 × g, 15 min at 4°C). The new supernatants were discharged, and the pellet was thoroughly resuspended in 10 ml TBS buffer. The latter centrifugation and resuspension were repeated four times. Following the final centrifugation, the pellet was dissolved in 1 ml TBS buffer. Platelet count was determined and corrected to 300× 10 9 /L by adding a balanced amount of TBS buffer. The platelet/phospholipids concentrate was stored frozen at −80°C in 500 μl aliquots.
Preparation of PPP WB was centrifuged for 25 min at 2,800 × g. PPP used for titration experiments with activator and addition of phospholipids was stored in aliquots at −80°C for at least 1 h, thawed for 10 min in a 37°C water bath, and finally ultra centrifuged at 13,800 × g for 3 min.
Preparation of PRP WB was centrifuged for 15 min at 114 × g. Platelet count was measured using a counting chamber (Thoma, assistant, Sondheim, Germany) and phase-contrast microscopy. PRP was adjusted to the predetermined platelet count by adding PPP.
Laboratory protocol
Titration experiments with activators WB, PPP, or PRP were transferred to prewarmed ROTEM plastic cups using volumes of 300 µl. Twenty microliters of buffer (HEPES 20 mM, NaCl 150 mM pH 7.4) or 20 µl tissue factor or synthasil diluted was added providing final tissue factor/synthasil concentrations at 1:17, 1:170, 1:1,700, 1:17,000, and 1:170,000. Coagulation was initiated and recalcified by addition of a calcium chloride containing buffer (HEPES 20 mM, NaCl 150 mM, and CaCl 200 mM pH 7.4).
Platelet count titration studies PRP with fixed platelet counts at 500×10 9 /l, 250×10 9 /l, 125×10 9 /l, 64×10 9 /l, 32×10 9 /l, 16×10 9 /l, 8×10 9 /l, and 0× 10 9 /l was transferred to prewarmed ROTEM plastic cups at volumes of 300 µl. Twenty microliters of buffer (HEPES 20 mM, NaCl 150 mM pH 7.4) was added, and coagulation 
Data interpretation
Data are presented using qualitative and semiquantitative descriptive statistics.
Results
Non-activated blood
Following recalcification only (e.g., omitting activator), WB had the shortest clot initiation, followed by PRP and PPP ( Table 1) . The MaxVel and MCF were highest in PRP, followed by WB and PPP, respectively (Table 1) .
Titration experiments with activators
In PPP, PRP, and WB, increasing concentrations of activator shortened the time of clot initiation. Noteworthy, following activation with lower concentrations of the contact activator, the CT initially remained stable; however, at higher concentrations, the CT shortened, although not Data presented as mean ± SE; n=3
MaxVel maximum velocity, MCF maximum clot firmness reaching the levels seen following activation with tissue factor. The propagation phase of clot formation was accelerated following increasing concentrations of activator. However, the pattern of the changes was distinctly different following activation with TF as compared with the contact activator. Thus, with increasing concentration of TF, the MaxVel grew to reach a maximum value; with excess amounts, it seemed to decline. The finding was consistently observed in PPP, PRP, and WB. At the selected concentrations of the contact activator, the MaxVel revealed a concentration-dependent increase. The MCF was highest in PRP, followed by WB and PPP, likely reflecting the total platelet count. Following activation with either TF or the contact activator at various concentrations, the MCF was unchanged (Fig. 1a-c) .
Platelet count titration
The concentration of platelets is of crucial importance for the rate-specific characteristics of clot formation. In particular, the MaxVel of clot formation revealed concentration-dependent changes; the higher the platelet count, the higher the maximum rate of clotting. Platelet counts below 100×10 9 /l caused a prolongation of the clot initiation. The changes in clot initiation were mainly visible following activation with low concentrations of contact activator, although also noticeable following activation with low concentrations of TF. The MCF increased independently of the type and concentration of activator and reached a plateau at platelet counts greater than 200×10 9 / l (Fig. 2a-c) .
Phospholipid titration studies
Increasing amounts of phospholipids induced a marked shortening in the clot initiation and increased clot propagation, in particular, when using low concentrations of activator. Furthermore, the importance of phospholipids seemed to be most pronounced following the use of contact activator. At high concentrations of the activator, the impact of phospholipids was less prominent. The MCF remained unaffected by increasing concentrations of phospholipids, and similar to observations gained from other experimental conditions, the amplitude was independent of the type and concentration of activator (Fig. 3a-c) .
Discussion
The present study demonstrates considerable differences in thromboelastometry parameters of dynamic coagulation when comparing PPP with PRP or WB as test medium. Furthermore, the data emphasized characteristic differences depending on the type and concentration of activator. Finally, titration experiments with increasing concentrations of platelets and phospholipids verified that these components play a crucial role in the dynamics of clot formation.
In recent years, several studies have been published on measurement of thromboelastography/thromboelastometry clotting profiles in order to describe dynamic characteristics of the coagulation system in various experimental and clinical settings. Examples include investigations of the contribution of selected coagulation factors [7] , the effect of vasoactive agents, platelet agonists, and anticoagulants [22, 23] , as well as assessment of storage of donor platelets [24] . Some studies have revealed that different types of activators provide different results in various clinical scenarios, such as, e.g., the effect of aprotinin on various activators [25] .
Data from this study indicate that the dynamic characteristics of coagulation as evaluated by thromboelastometry are highly dependent on the experimental conditions selected. The choice of test media is important since PPP, PRP, or WB show pronounced differences in dynamic parameters. The maximum velocity is highest in PRP, followed by WB and PPP. Furthermore, the CT is longer in PPP as compared with PRP and WB, respectively. When a given volume of WB is recalcified, the calcium distributes primarily in the plasma volume, which is only a fraction of the total, due to the substantial red cell volume. This would not be the case for PPP or PRP. So, the WB samples probably end up with a higher plasma calcium concentration than PRP/PPP. This could explain the shorter clot initiation times of WB. The presence of platelets and phospholipids is an important determinant for these observed differences. As visualized by the results, PPP as a test medium is very sensitive to phospholipids. Thus, contamination with even small amounts of phospholipids in PPP, such as microparticle contamination, may contribute as a serious confounder and compromise the reproducibility. Furthermore, the choice of activator and its concentration may seriously change the properties of coagulation kinetics and their correct interpretation. Data further illustrate a considerable diversity in dynamic parameters using different activators. The CT and maximum velocity are parameters showing the most pronounced differences, in particular, following use of minute (diluted) amounts of activator. Following increasing concentrations of tissue factor or contact activator, the CT is shortened. However, even following a high degree of activation, there is still significant differences between tissue factor and contact activator. Increasing the intensity of contact activation results in increasing maximum velocity. The greater importance of phospholipid to activation by the contact initiator may be because the tissue factor reagent already has a fairly large amount of phospholipid in it to keep the TF soluble. Paradoxically, it appears that increasing concentrations of tissue factor activation gave place to a maximum value followed by a slight decline. A plausible explanation could be that moderate amount of tissue factor triggers thrombin generation via activation of FX via TFFVIIa and activation of FX via TF-FVIIa-induced activation of FIX. Thus, defects of the intrinsic FIXaFVIIIa complex can be detected in diluted prothrombin time. With the highest concentration of tissue factor, it may be speculated that thrombin generation predominantly gets activated via FXa triggered by TF-FVIIa without involvement of the intrinsic FIXaFVIIIa complex. The FIXaFVIIIa complex is a significantly more potent activator of FX than TF-FVIIa [14] . Another explanation could be that factor VIIa is saturated with high TF. Tissue factor containing phospholipid vesicles could be unoccupied by factor VIIa. If factor X or factor IX binds to these particles, there will not be a productive VIIa/TF complex to activate them. A potential limitation of the study is the low sample size of n=3. However, the study aimed to describe characteristic changes and not to evaluate interindividual variability or reference ranges. Another shortcoming of the protocol was that we did not include various sources and formulation of tissue factor and contact activator. It has been reported that various sources and formulations of tissue factor may display distinctly different activities as evaluated by a specific double-monoclonal antibody fluorescence-based immunoassay [26] . Several other analytical variables have not been investigated. Recent pioneering work by Mann et al. [27] has shown that citrate chelation and recalicification itself may significantly change the dynamics of thrombin generation and thromboelastometry clotting profiles, in particular when the process is activated with minute amounts of tissue factor. Furthermore, our study did not account for changes related to spontaneous artificial contact activation, a process that might have been quenched by using a corn trypsin inhibitor [28] . It is also important to notify that lack of flow in the test system and the lack of interaction with the vascular endothelium constitute another important limitation of thromboelastometry. The present study focused on clot initiation, clot propagation, and clot firmness. Increasing numbers of studies have been utilizing thromboelastography/thromboelastometry to address dynamic changes of clot strength or resistance against accelerated fibrinolytic activity [29] [30] [31] ; however, that was not addressed in the present methodologic evaluation. Finally, it would have been interesting to correlate our findings to direct measurement of thrombin generation, although recent studies have demonstrated that thromboelastometry represents a useful surrogate measure of thrombin generation in WB in vitro [32] , as well as coagulation activation in vivo, when the blood is only recalcified [33] .
So far, there is no agreed consensus on preanalytical procedures, the preferred test medium, as well as the type and concentration of activator. Current practice allows for considerable variations in the type and concentration of activators used. Consistent with previous observations, our results demonstrate that extrinsic and contact activation exerts different effects on thromboelastometry variables. Several investigations made in our laboratory have suggested that activation with low-dose tissue factor may be advantageous since this pathway appears to represent the physiological initiator of in vivo WB clot formation and allows for phenotypic characterization of a broad spectrum of coagulation disorders. However, based on previous and ongoing studies, it seems rational to use corn trypsin inhibitor-stabilized citrated WB [34, 35] .
In conclusion, the results of the present study suggest that evaluation of coagulation kinetics using thromboelastometry requires critical interpretation based on a series of experimental variables such as test medium, type, and concentration of activator, as well as the presence and concentration of phospholipids in the test reagents.
